Development setbacks overshadow Basilea's reduced net loss
This article was originally published in Scrip
Executive Summary
Basilea has confirmed that the US Phase III study of its oral treatment for severe chronic hand eczema, Toctino (alitretinoin), is delayed by 12 months. The results are now due at the end of 2011, with a filing expected for 2012, the company said while reporting its half-year financial results that showed a reduced net loss for the company in the first half.